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Introduction {#sec005}
============

Vitamin D plays an important role in promoting healthy pregnancy and fetal development, and poor vitamin D status has been associated with adverse maternal and infant health \[[@pone.0157262.ref001]\]. There is also evidence that pregnancy risks may be mitigated by vitamin D supplementation, although the optimal daily dose is not clear \[[@pone.0157262.ref002]\]. Health Canada \[[@pone.0157262.ref003]\] and the Institute of Medicine (IOM) \[[@pone.0157262.ref004]\] have recommended 600 IU/day intake of vitamin D during pregnancy. The IOM set these guidelines on optimizing bone health of pregnant women (and ensuring bone growth in the infant) \[[@pone.0157262.ref004]\]. Currently, there is a lack of consensus on what constitutes vitamin D sufficiency. The IOM has recommended a 25(OH)D cut point of \>50 nmol/L to define vitamin D sufficiency, as this level is associated with prevention of the bone manifestations of vitamin D deficiency (rickets and osteomalacia) for 97.5% of Canadians and Americans. However, there is not universal agreement with the IOM recommendations, and others suggest that an optimal level for bone health might be somewhat higher. Osteoporosis Canada \[[@pone.0157262.ref005]\] and the Endocrine Society \[[@pone.0157262.ref006]\] set a serum concentration of \>75 nmol/L as the target for optimal bone health, and other experts have suggested concentrations \> 80 nmol/L \[[@pone.0157262.ref007]\].

Despite these recommendations, a recent study showed one-quarter of Canadians (ages 6--79 years) did not meet the Recommended Daily Allowance (RDA; daily intake level of a nutrient that is considered to be sufficient to meet the requirements of 97--98% of healthy individuals) through food sources alone. However, the daily use of vitamin D supplements contributed to a better 25-hydroxycholecalciferol (25(OH)D) status \[[@pone.0157262.ref008]\]. A combined analysis of two randomized clinical trials of 494 pregnant women taking 400, 2000, and 4000 IU/day vitamin D during pregnancy showed that vitamin D supplementation of 4000 IU/day was more effective in achieving serum concentrations ≥ 80 nmol/L than 400 and 2000 IU/day in all women and their neonates regardless of race, suggesting that the current dietary recommendation in the absence of supplementation in pregnancy may not be optimal \[[@pone.0157262.ref009]\]. However, these studies used sub-optimal quantification methods (radio-immunoassays) and did not consider the potential contribution of dietary vitamin D to total intake. A recent systematic review of vitamin D supplementation in pregnancy concluded that evidence is currently insufficient to support definite clinical recommendations regarding vitamin D supplementation in pregnancy. This review highlighted the extremely heterogeneous evidence in regards to definition of serum vitamin D concentration threshold and the lack of high-quality interventional studies \[[@pone.0157262.ref010]\].

The best clinical laboratory indicator of vitamin D status is the blood concentration of 25(OH)D \[[@pone.0157262.ref004]\]. It is important to use an assay methodology that can identify both 25-hydroxyergocalciferol (25(OH)D~2~) and 25(OH)D~3~, as both metabolites are metabolically active and both are available as dietary supplements and in fortified foods. In addition, recent studies have shown the epimeric form of 25(OH)D~3~ contributes significantly to measured 25(OH)D~3~ when methods are unable to separate the less active epimer \[[@pone.0157262.ref011], [@pone.0157262.ref012]\]. We recently showed that not separating out plasma 3-epi-25-hydroxycholecalciferol (3-epi-25(OH)D~3~) from vitamin D status calculation underestimates the classification of pregnant women and their newborns at risk for vitamin D insufficiency (\>75 nmol/L) \[[@pone.0157262.ref013]\].

Although the literature regarding vitamin D in pregnancy is growing rapidly, several gaps in our knowledge remain, including the prevalence of vitamin D deficiency/ insufficiency during pregnancy and the intake of vitamin D during pregnancy needed to ensure optimal status. Our aims in the current study were to determine: a) if pregnant women were consuming the recommended vitamin D through diet alone or through diet and supplements, and b) if pregnant women can achieve the current reference range vitamin D status when their reported dietary intake of vitamin D met the current recommendations.

Methods {#sec006}
=======

This study is a secondary analysis of an established maternal and infant prospective cohort study. The APrON study ([A]{.ul}lberta [Pr]{.ul}egnancy [O]{.ul}utcomes and [N]{.ul}utrition; [www.ApronStudy.ca](http://www.ApronStudy.ca)) is a longitudinal cohort of pregnant women and their children residing in Calgary and Edmonton (Alberta, Canada). We used the APrON cohort data and analyzed the banked blood samples collected from the first 537 women recruited to APrON in their second trimester of pregnancy (whose dietary data had been cleaned and linked to the biomedical data). APrON recruited a total of 2191 women between March 2009 and July 2012, primarily through in-person contact at maternity clinics. Full details of the APrON study are described elsewhere \[[@pone.0157262.ref014]\].

Maternal dietary data {#sec007}
---------------------

### 24-hour recall {#sec008}

At each prenatal and postpartum visit, women were asked by a trained nutrition professional or registered dietitian to describe in detail the quantity and type of both food and beverages consumed in the previous 24-hour period midnight to midnight during each trimester and three months postpartum. Dietary food models were utilized to help increase accuracy of serving size estimates. The trained nutrition professional or registered dietitian also used probing tactics to obtain further information on cooking method, meal times, and food brands, as well as completeness of recall. Dietary recalls were read back to each participant for accuracy and comprehensiveness. Analysis of these records is described in detail elsewhere \[[@pone.0157262.ref015]\]. The estimated dietary intake of vitamin D from the 24-hour recall was not specifically validated against another dietary intake tool. However, intake from food and beverages only accounted for 39% of total vitamin D intake and the major source (39%) was from milk, which was consumed on a regular basis by participants during the second trimester of pregnancy. The major source for vitamin D was from the supplements; this data was obtained from the questionnaire that has been previously described in detail \[[@pone.0157262.ref015]\].

### Maternal Supplement Intake Questionnaire (SIQ) {#sec009}

Following enrollment, the Maternal Supplement Intake Questionnaire (SIQ) was administered by a trained nutrition professional to each participant once during each trimester of pregnancy and once at 3 months postpartum to determine current Natural Health Product (NHP) use including vitamin D. The SIQ was designed specifically for the APrON study and was initially used in a pilot study that included of fifty women in the APrON study who completed the questionnaire during their first and second visits to assess efficacy and the detail of information obtained \[[@pone.0157262.ref015]\]. Women were encouraged to bring in the supplement bottles they consumed that contain the Natural Product Number (NPN) that is linked to Health Canada's Licensed Health Products Database (LNHPD) \[[@pone.0157262.ref015]\]. If women did not bring in the supplement bottles, they reported the brand name, dosage, and frequency of consumption for each product during the period between visits. When a nutritional supplement could not be found in the LNHPD, the manufacturer's website was used to retrieve nutritional information. Since the SIQ was administered when the women began taking the supplements, those who were recruited at 14--26 weeks were able to provide supplement intake retrospectively for the first trimester. At follow-up visits, if women had begun or stopped supplements since their last visit, these adjustments were also made to their supplement intake information. A NHP database was created for this and other APrON studies that linked the NPN to the nutrient content of each supplement. Supplements not in the LNHPD were provided their own unique code for identification purposes. The most common NHPs were used as a default if the nutrient content of the supplement was unknown or if not enough information was provided about the supplement. A detailed conversion method was developed so as to not overestimate intake if participants had taken a supplement for a fraction of the time point or if they switched supplements at any point during that time period. Corrections were applied based on daily use (numbers of days/ week) and trimester (number of weeks/ trimester). Information on supplement intake recording and analysis for the APrON study has been previously reported \[[@pone.0157262.ref015]\]. All extreme values of vitamin D (\>4000, which is the upper limit recommended intake) were reviewed by reviewing the actual SIQ. All values were correct and it was plausible that women could exceed the recommendation. All NHPs were available through health food shops. No participants took a separate vitamin D supplement through a prescription, although a prenatal supplement would have been recommended by their physician. Calcium intake among women in the APrON cohort has not yet been estimated. However, previous studies have shown calcium source during pregnancy is predominately from diet rather than supplements \[[@pone.0157262.ref016]--[@pone.0157262.ref020]\]. These studies showed calcium supplement contributed less than 20% to the total intake \[[@pone.0157262.ref016]--[@pone.0157262.ref020]\].

Measurement of vitamin D status {#sec010}
-------------------------------

Maternal blood was collected at each clinic visit by a certified phlebotomist. The majority of APrON participants were recruited in their second trimester; therefore, we used the blood samples taken from their second trimester for this study (consequently, the dietary data from the second trimester were used for analysis). All frozen collected plasma was assayed alongside plasma quality control samples and standard reference materials using a clinically validated LC-MS/MS assay at the laboratory of Doctor's Data Inc. \[[@pone.0157262.ref013]\], which measured 25(OH)D~2~, 25(OH)D~3~, and 3-epi-25(OH)D~3~ and demonstrates an intra-assay coefficient of variability of 4.6% at 28.3 nmol/L, 3.3% at 83.9 nmol/L, and 3.9% at 5.8 nmol/L for 25(OH)D~2~, 25(OH)D~3~, and 3-epi-25(OH)D~3~, respectively. Information on processing blood samples and integrity of plasma samples has been previously reported \[[@pone.0157262.ref013]\]. The concentrations of 25(OH)D~2,~ 25(OH)D~3,~ and 3-epi-25(OH)D~3~ in plasma were determined using LC-MS/MS (the National Institute of Standard and Technology (NIST) standards and Vitamin D External Quality Assessment Scheme (DEQAS) procedures were followed), as previously described \[[@pone.0157262.ref013]\].

Statistical analysis {#sec011}
--------------------

Results are presented for plasma 25(OH)D~2~, 25(OH)D~3,~ and 3-epi-25(OH)D~3~ in terms of means and standard deviations (SD) and medians and interquartile ranges (IQR). The prevalence rates of vitamin D deficiency and insufficiency in women were estimated as percentages with 95% confidence interval (CI). Plasma concentrations of 25(OH)D at \<25 nmol/L \[[@pone.0157262.ref003], [@pone.0157262.ref004]\], \<50 nmol/L \[[@pone.0157262.ref003], [@pone.0157262.ref004]\], and \<75 nmol/L \[[@pone.0157262.ref005], [@pone.0157262.ref006]\] were used to reflect several laboratory definitions of vitamin D status currently used. The prevalence rates of vitamin D insufficiency with and without the epimer were compared using McNemar's chi-square test. The correlation between maternal 25(OH)D~3~ and 3-epi-25(OH)D~3~ was determined using the Pearson correlation coefficient test. Repeated measures ANOVAs were used to examine the difference between the reported dietary intakes across the three trimesters. As reported dietary and supplemental vitamin D intakes were not normally distributed, the natural log transformation of the skewed variables was used for the test.

A multiple linear regression analysis was used to examine the association between women's plasma 25(OH)D (D~2~ + D~3~) concentration and their reported dietary vitamin D intake in supplements and diet adjusted for the potential covariates of maternal age, maternal BMI at second trimester, season (summer from May 01-Oct 31 and winter from Nov 01-Apr 30), and race (Caucasian *vs*. non-Caucasian) \[[@pone.0157262.ref007]\]. Again, as the dependent variables (dietary and supplemental vitamin D intakes) and independent variables (25(OH)D~3~ and 3-epi-25(OH)D~3~) were not normally distributed, the natural log transformation of the skewed variables was used for the test.

In addition, plasma levels were dichotomized as deficient/insufficient versus adequate, and multiple logistic regression analysis was used to estimate the odds of insufficiency (\<50 *vs*. ≥ 50 and \<75 *vs*. ≥ 75 nmol/L) as a function of reported vitamin D intake, adjusted for the same covariates (odds ratios and their corresponding 95% CIs). All analyses were conducted using Stata statistical software (version 14) and SPSS (version 22). P-values \< 0.05 were considered statistically significant.

Results {#sec012}
=======

Blood samples from 537 women from their second trimester of pregnancy who had complete dietary and clinical data were analyzed (sample characteristics in [Table 1](#pone.0157262.t001){ref-type="table"}). In addition, we compared plasma samples from the first and second trimester of 83 APrON participants who were recruited in the first trimester. We measured vitamin D metabolites with LC-MS/MS and showed that, except for 25(OH)D~2~, there were no significant differences between the two trimesters for any other metabolite ([Table 2](#pone.0157262.t002){ref-type="table"}).

10.1371/journal.pone.0157262.t001

###### Characteristics of Participants in a Longitudinal Cohort of Pregnant Women in Alberta, Canada.

![](pone.0157262.t001){#pone.0157262.t001g}

  Characteristics of Participants                                         Overall (n = 537)
  ----------------------------------------------------------------------- ----------------------
  Age, y                                                                  31 ± 4 (n = 537)
  Gestational age[^a^](#t001fn001){ref-type="table-fn"}                   19.6 ± 3.4 (n = 502)
  **Race, %**                                                             (n = 513)
  Black                                                                   1
  Caucasian                                                               87
  Others                                                                  12
  **Family annual income**[^b^](#t001fn002){ref-type="table-fn"}**, %**   (n = 537)
  \< \$70,000                                                             19
  ≥ \$70,000                                                              81
  **Type of education, %**                                                (n = 514)
  \< High school                                                          2
  High school                                                             8
  Trade school                                                            20
  Undergraduate                                                           47
  Postgraduate                                                            23
  **Prior births ≥37 weeks gestation, %**                                 (n = 537)
  0                                                                       58
  1                                                                       32
  2                                                                       8
  3                                                                       1
  4                                                                       0.4
  **Season of sampling, %**                                               (n = 546)
  Spring[^c^](#t001fn003){ref-type="table-fn"}                            33
  Summer[^d^](#t001fn004){ref-type="table-fn"}                            25
  Fall[^e^](#t001fn005){ref-type="table-fn"}                              14
  Winter[^f^](#t001fn006){ref-type="table-fn"}                            28
  BMI[^g^](#t001fn007){ref-type="table-fn"}                               26 ± 5 (n = 537)

^a^At time of blood sample.

^b^Canadian dollars.

^c^March 20-June 20.

^d^June 21-September 20.

^e^September 21-December 20.

^f^December 21-March 19.

^g^Second trimester.

10.1371/journal.pone.0157262.t002

###### Distribution of Plasma Vitamin D Metabolites in the First and Second Trimesters of Pregnancy in a Longitudinal Cohort of Pregnant Women and Their Infants in Alberta, Canada.

![](pone.0157262.t002){#pone.0157262.t002g}

  Trimesters of Pregnancy            N     Range (nmol/L)   Mean ± SD (nmol/L)   Median (25^th^ to 75^th^) (nmol/L)
  ---------------------------------- ----- ---------------- -------------------- ------------------------------------
  **First trimester**                                                            
  Total 25(OH)D                      83    40.1--161.1      93.3 (25.6)          94.1 (75.4--108.8)
  Total 25(OH)D~3~                   83    40.1--161.2      92.2 (25.6)          93.3 (73.8 to 108.2)
  Total 25(OH)D~2~                   83    0--6             1 (1.2)              0.6 (0 to 1.7)
  Total 3-epi-25(OH)D~3~             83    2.1--14.7        5.4 (2)              5.0 (4.1 to 6.5)
  **Second trimester**                                                           
  Total 25(OH)D                      537   27.1--196.8      95.3 (25)            92.7 (79 to 109.4)
  Total 25(OH)D~3~                   537   26.1--194.3      91.9 (25)            89.2 (74.7 to 106)
  Total 25(OH)D~2~                   537   0--21.2          3.4 (2.9)            2.9 (1.7 to 4.4)
  Total 3-epi-25(OH)D~3~             537   0.7--19.4        5.6 (2.2)            5.2 (4.1 to 6.7)
  Total 25(OH)D~+~3-epi-25(OH)D~3~   537   29.7--214.3      100.9 (26.6)         98.1 (83.4 to 116.2)

The paired t-test showed a significant difference between first and second trimester for total 25(OH)D~2~ (P\<0.0001), but no significant difference for total 25(OH)D~3~ (P = 0.52), total 25(OH)D (P = 0.46), and total 3-epi-25(OH)D~3~ (P = 0.13).

**Reported dietary vitamin D intake (diet and supplements)**. [Table 3](#pone.0157262.t003){ref-type="table"} shows the reported intake from diet and supplements for all the trimesters of pregnancy. There were 537 completed SIQs and 528 completed 24-hour recalls from the second trimester, and 526 participants provided complete data from both diet and supplements. The median (IQR) overall reported intake of vitamin D (IU) from the combined (24-hour recall + SIQ) was 568 (404) for the first trimester, 600 (472) for the second trimester, and 634 (516) for the third trimester ([Table 3](#pone.0157262.t003){ref-type="table"}).

10.1371/journal.pone.0157262.t003

###### Distribution of Reported Dietary Vitamin D Intake (IU/day) in the First, Second, and Third Trimesters of Pregnancy in a Longitudinal Cohort of Pregnant Women and Their Infants in Alberta, Canada.

![](pone.0157262.t003){#pone.0157262.t003g}

  Trimester                                               N     Mean ± SD   Min to Max   Median (25^th^ to 75^th^)
  ------------------------------------------------------- ----- ----------- ------------ ---------------------------
  **First trimester**                                                                    
  Supplement intake                                       398   451 ± 530   0 to 4250    320 (200 to 400)
  Dietary intakes                                         113   185 ± 146   5 to 840     165 (71 to 264)
  Overall intakes[^a^](#t003fn001){ref-type="table-fn"}   112   704 ± 554   32 to 4482   568 (407 to 810)
  **Second trimester**                                                                   
  Supplement intake                                       537   590 ± 690   0 to 8400    400 (250 to 544)
  Dietary intakes                                         528   218 ± 173   0 to 1350    175 (98 to 298)
  Overall intakes[^a^](#t003fn001){ref-type="table-fn"}   526   812 ± 722   38 to 9209   600 (449 to 921)
  **Third trimester**                                                                    
  Supplement intake                                       493   634 ± 680   0 to 5427    400 (250 to 689)
  Dietary intakes                                         471   236 ± 193   0 to 1633    192 (105 to 321)
  Overall intakes[^a^](#t003fn001){ref-type="table-fn"}   469   872 ± 695   28 to 3790   634 (469 to 985)

^a^Overall intakes: supplements + diet; the repeated measures ANOVA showed no significant difference in log transformed mean vitamin D intake from diet (24 hour recall) (P = 0.13), but a significant difference in log transformed mean intake from supplement across all trimesters (P\<0.001), resulting in a significant difference in total vitamin D intake across all trimesters (P = 0.004).

A repeated measures ANOVA showed no significant difference in log transformed mean reported vitamin D intake from diet (24-hour recall) (P = 0.13) between time-points. However, there was a significant difference in log transformed mean reported intake from supplements between time points (first *vs*. second *vs*. third) (P\<0.001), resulting in a significant increase in total reported vitamin D intake from trimester one to trimester three (P = 0.004). Fifty-four percent of pregnant women reported taking 600 and higher IU/day of vitamin D through their diet and supplements in the second trimester of pregnancy; maternal characteristics were not different between those who reported taking \<600 IU/day vitamin D *vs*. ≥600 IU/day, except university degree (67% *vs*. 78%, respectively) (data are not shown).

**Maternal 25(OH)D**~**2**~**, 25(OH)D**~**3**~ **and 3-epi-25(OH)D**~**3**~ **concentrations**. All samples were found to have detectable concentrations of 25(OH)D~2~, 25(OH)D~3,~ and 3-epi-25(OH)D~3~. Median (25^th^-75^th^) maternal plasma concentration for 25(OH)D~2~ was 2.9 (1.7--4.4) nmol/L. Vitamin D supplements in Canada are almost all vitamin D~3~; however, vitamin D~2~ is still available by prescription and may be obtained from some food sources. Median (25^th^-75^th^) maternal plasma 25(OH)D~3~ was 89.2 (74.4--106) nmol/L, and for plasma 3-epi-25(OH)D~3~ was 5.2 (4.1--6.7) nmol/L ([Table 2](#pone.0157262.t002){ref-type="table"}). No participant had 25(OH)D (excluding 3-epi-25(OH)D~3~) plasma concentrations \<25 nmol/L, 12 (2%, 95% CI: 1.1--3.5) women had plasma concentrations \<50 nmol/L, and 100 (19%, 95% CI: 15.3--22.2) women had concentrations in the \<75 nmol/L range. The relationship between 25(OH)D~3~ and 3-epi-25(OH)D~3~ is shown in [Fig 1](#pone.0157262.g001){ref-type="fig"}.

![Scatter plot of plasma 3-epi-25(OH)D~3~ and 25(OH)D~3~ in pregnant women during second trimester of pregnancy in a longitudinal cohort of pregnant women and their infants in Alberta, Canada (n = 537).\
Pearson correlation coefficient showed a significant correlation between 25(OH)D~3~ and 3-epi-25(OH)D~3~ (r = 0.69, P\<0.001).](pone.0157262.g001){#pone.0157262.g001}

**The effect of 3-epi-25(OH)D**~**3**~ **on the classification of 25(OH)D sufficiency**. Three-epi-25(OH)D~3~ was detected (\>1.0 nmol/L) in all maternal samples. Three-epi-25(OH)D~3~ comprised 5.0% of total 25(OH)D. When 3-epi-25(OH)D~3~ was excluded from the vitamin D estimations, 19% of women were considered to have levels \<75 nmol/L; however, with 3-epi-25(OH)D~3~ included, the percentage of women with vitamin D concentration of \<75 nmol/L decreased to 12%. The observed difference in the risk of insufficiency was significant (P\<0.001). As we had very small numbers of participants with 25(OH)D concentrations \<50 nmol/L, the estimate of insufficiency at this level with 3-epi-25(OH)D~3~ excluded was 2%, compared to 1.5% when it was included (P = 0.125).

**Association between women's plasma 25(OH)D and 3-epi-25(OH)D**~**3**~ **concentration and maternal reported vitamin D intake**. The relationship between 25(OH)D and 3-epi-25(OH)D~3~ and vitamin D intake are shown in [Fig 2a and 2b](#pone.0157262.g002){ref-type="fig"}. There was a significant association between maternal plasma 25(OH)D and total reported vitamin D intake during the second trimester of pregnancy (β: 0.09, 95% CI: 0.06 to 0.13) in an adjusted linear regression model. Season of sampling and race were also significantly associated with 25(OH)D concentration ([Table 4](#pone.0157262.t004){ref-type="table"}).

![Absolute concentrations of (A) plasma 25(OH)D, and (B) plasma 3-epi-25(OH)D~3~ versus maternal vitamin D intake (IU/day) in a longitudinal cohort of pregnant women and their infants in Alberta, Canada.\
Black horizontal lines in each box represent medians; edges of each box represent 25^th^ and 75^th^ percentiles; the lines extending from each box represent 1.5 times the interquartile range; outliers are shown as stars.](pone.0157262.g002){#pone.0157262.g002}

10.1371/journal.pone.0157262.t004

###### Multiple Regression Model for 25(OH)D~3~, 3-epi-25(OH)D~3~, and %3-epi-25(OH)D~3~ in a Longitudinal Cohort of Pregnant Women and Their Infants in Alberta, Canada.

![](pone.0157262.t004){#pone.0157262.t004g}

                                                 25(OH)D[^a^](#t004fn001){ref-type="table-fn"}, β(95% CI)   P          3-epi-25(OH)D~3~[^a^](#t004fn001){ref-type="table-fn"}, β(95% CI)   P
  ---------------------------------------------- ---------------------------------------------------------- ---------- ------------------------------------------------------------------- ----------
  Vitamin D intake                               0.09 (0.4, 0.14)                                           \<0.0001   0.13 (0.07, 0.18)                                                   \<0.0001
  Season[^b^](#t004fn002){ref-type="table-fn"}   0.09 (0.04, 0.14)                                          \<0.0001   0.03 (-0.05, 0.11)                                                  0.4
  Age                                            0.010 (-0.01, 0.01)                                        0.8        -0.01 (-0.01, 0.01)                                                 0.8
  BMI                                            -0.01 (-0.01, 0.01)                                        0.4        -0.01 (-0.02, -0.01)                                                0.03
  Race[^c^](#t004fn003){ref-type="table-fn"}     0.12 (0.05, 0.20)                                          0.001      0.14 (0.01, 0.2)                                                    0.01

^a^nmol/L.

^b^Summer (May 01-October 31) *vs*. winter (November 01-April 30).

^c^Caucasian *vs*. non-Caucasian.

In addition, the association between maternal plasma 3-epi-25(OH)D~3~ and total reported vitamin D intake during the second trimester was significant (β: 0.13, 95% CI: 0.07 to 0.18), as well as maternal BMI at second trimester and race in an adjusted linear regression model ([Table 4](#pone.0157262.t004){ref-type="table"}). Plasma 3-epi-25(OH)D~3~ was significantly associated with reported vitamin D intake from supplements but not diet (data not shown). Women with plasma concentration of \<75 nmol/L reported consuming less vitamin D (diet + supplements) compared to those with plasma concentration ≥ 75 nmol/L (median (IQR): 492 (320) IU/day *vs*. 622 (540) IU/day). In addition, when plasma levels were dichotomized at \<50 *vs*. ≥ 50 and \<75 *vs*. ≥ 75 nmol/L in a multiple logistic regression model, higher reported intake of vitamin D was associated with greater odds of vitamin D sufficiency during the second trimester within both ranges (OR: 2.17, 95% CI: 1.48 to 3.16 for ≥75 nmol/L and OR: 3.21, 95% CI: 1.17 to 8.83 for ≥50 nmol/L). Maternal age, BMI, season, and ethnicity were not significant effect modifiers or confounders in the model (data not shown).

Discussion {#sec013}
==========

To our knowledge, this is the largest study to date to show 44% of pregnant women with a higher socioeconomic status reported vitamin D intake (diet and supplements) not meeting the dietary reference intakes (DRI) recomendations. Using LC-MS/MS, we separated epimer from estimation of vitamin D status and were able to accurately estimate the prevalence of vitamin D insufficiency in our pregnant women. We also found that 20% of pregnant women had vitamin D concentraion \<75 nmol/L, despite more than half of these women reporting taking more than 600 IU/day of vitamin D (the current RDA) based on their reported intake from diet and supplements.

In Northern countries such as Canada, the latitude of the country further reduces the potential contribution of dermal synthesis to the maintenance of appropriate vitamin D concentrations, placing women at greater risk for vitamin D deficiency/ insufficiency \[[@pone.0157262.ref021], [@pone.0157262.ref022]\]. There are few natural sources of vitamin D in the food supply: primarily fatty fish, beef liver, and egg yolk \[[@pone.0157262.ref007]\]. In North America, the main dietary source of vitamin D is through fortified dairy and dietary supplements \[[@pone.0157262.ref023], [@pone.0157262.ref024]\]. Canadian Community Nutrition Intakes data for non-pregnant women of child-bearing age (19--50 years) reported that 90% of Canadian women are not consuming the current recommendations for vitamin D through their diet \[[@pone.0157262.ref025]\]. In the current study, we showed that pregnant women are taking small amounts of vitamin D from food and beverages in their diet (\<200 IU/day), and they are relying on supplemental sources of vitamin D to meet the current DRIs. We showed consuming lower doses of vitamin D (\< than the current DRI) is associated with a higher rate of vitamin D insufficiency (\>75nmol/L). Our findings are supportive of a growing body of literature suggesting that the recommended dose of vitamin D during pregnancy is inadequate in preventing vitamin D deficiency/insufficiency \[[@pone.0157262.ref026]\]. A recent study of maternal vitamin D status at third trimester of pregnancy and postpartum periods of 467 pregnant women in Toronto showed persistent vitamin D deficiency/ insufficiency in two-thirds of participants despite taking 400 IU/day of vitamin D through their prenatal vitamin D \[[@pone.0157262.ref027]\]. Another recent American longitudinal study of 193 pregnant women from mid-pregnancy to birth showed consuming a prenatal vitamin D supplement (334 IU/day) did not prevent precipitous drops in maternal plasma 25(OH)D concentration \[[@pone.0157262.ref028]\]. In fact, randomized clinical trials of 2000 and 4000 IU/day vitamin D during pregnancy have shown that vitamin D supplementation of 4000 IU/day was more effective in achieving serum concentrations ≥80 nmol/L of vitamin D \[[@pone.0157262.ref009]\]. One strength of the current study is its use of a quantification method capable of accurately measuring 25(OH)D (separating epimer) and adding the potential contribution of dietary vitamin D to the total intake estimate.

In addition, we demonstrated the presence of 3-epi-25(OH)D~3~ in all our pregnant women's plasma samples across pregnancy (second trimester), and that including this epimer in the measurement of vitamin D status significantly influenced the classification of prevalence of vitamin D sufficiency in pregnancy. This finding is consistent with our previous study showing epimer can alter vitamin D status estimation of pregnant women at the time of delivery and in their cord blood \[[@pone.0157262.ref013]\]. Although previous studies have shown factors like age, season, and vitamin D supplementation affect 3-epi-25(OH)D~3~ \[[@pone.0157262.ref029], [@pone.0157262.ref030]\], in our study the only factor positively correlated with level of the 3-epi-25(OH)D~3~ was vitamin D intake. The fact that season significantly affected 25(OH)D concentration but not 3-epi-25(OH)D~3~ suggests that vitamin D supplements could be a source for 3-epi-25(OH)D~3~ as shown in a previous study \[[@pone.0157262.ref030]\]. Although the physiological role of the C~3~-epimerization pathway has not yet been elucidated, there are indications that it has some anti-proliferative activity and differentiation activity only at levels of approximately 10%-30%, respectively, compared to non-epimeric vitamin D metabolites \[[@pone.0157262.ref011], [@pone.0157262.ref012]\]. This has led to the suggestion that the C~3~-epimer should not be included in calculating 25(OH)D concentrations in serum. Clinical data has indicated that 9% of infants and 3% of adults would be misclassified as sufficient if the epimer had not been identified in the quantification \[[@pone.0157262.ref011]\]. These findings emphasize the need for further identification of the functional role and clinical significance of 3-epi-25(OH)D~3~ in the assessment of vitamin D status in pregnant women, given the fact that the cut-off for vitamin D sufficiency in pregnancy is unclear.

One of our study's limitations is that the cohort was skewed toward women with annual income \>\$70,000 (2014 Canadian dollars), which could influence the generalizability of study findings to the entire population. In our study, only 20% of women had 25(OH)D \<75 nmol/L, which is much lower than what is reported in other Canadian studies. The Canadian Health Measures Survey (CHMS) found that 63% of non-pregnant women aged 20--39 years had 25(OH)D \<75 nmol/L \[[@pone.0157262.ref008]\], and a re-analysis of CHMS data, with standardization of the assay methodology, showed that 40% of women aged 19--30 years and 36% of women aged 31--50 years had 25(OH)D \<50 nmol/L \[[@pone.0157262.ref031]\]. A study from Toronto showed that 65% of pregnant women had 25(OH)D \<75 nmol/L and 31% had 25(OH)D \<50 nmol/L \[[@pone.0157262.ref027]\]. Similarly, a study from Vancouver found that 65% of pregnant women had 25(OH)D \<75 nmol/L and 24% had 25(OH)D \<50 nmol/L \[[@pone.0157262.ref032]\]. A recent study showed that IOM recommendation is probably too low to achive 50 nmol/L for 97.5% of the populataion, although we did not show that in our study \[[@pone.0157262.ref033]\]. The lower rate of vitamin D insufficiency in our study could be related to the cohort characteristics involving very educated, high socio-economic status pregnant women. Still, we found a wide distribution of vitamin D intake and status, which allowed us to study the association between maternal reported vitamin D intake and maternal vitamin D concentrations. Furthermore, estimates from the 24-hour recall tool may be susceptible to usual dietary misreporting, involving inaccurate food descriptions and portion size estimation. However, given that vitamin D from foods in Canada makes such a small overall contribution to vitamin D dietary intake ([Table 3](#pone.0157262.t003){ref-type="table"}), the accuracy of the 24-hour recalls is less critical in estimating women's total vitamin D intake.

Another limitation of our study is the lack of information on sun exposure, skin color, and clothing coverage of participants. We used data on season as a proxy for sun exposure in our study. Studies \[[@pone.0157262.ref034], [@pone.0157262.ref035]\] have shown that ultraviolet radiation (UVR)-derived vitamin D is an important factor in 25(OH)D~3~ concentration. A Canadian study \[[@pone.0157262.ref036]\] of young adults found seasonal differences in 25(OH)D concentraions. Recent sun exposure predicted 25(OH)D concentration in the fall. The fall 25(OH)D concentration explained 45% of variation in 25(OH)D concentration in winter. Thus, it appears that although winter UVR exposure may be insufficient, variations in summer sun exposure will alter fall 25(OH)D concentration and thus indirectly influence winter vitamin D levels. Another recent Canadian study \[[@pone.0157262.ref035]\] showed summer sun exposure was a predictor of 25(OH)D~3~ concentration but fall sun exposure was not, which may be related to lower vitamin D-weighted climatological UV in Toronto during the fall. Although Calgary averages the greatest number of days/year with sunlight in Canada, study of adult participants in Calgary found a modest edffect of season on 25(OH)D concentration and serum PTH \[[@pone.0157262.ref037]\]. We showed that season of sampling and race were significantly associated with 25(OH)D concentration. While the current Canadian Cancer Society recommendations \[[@pone.0157262.ref038]\] are to avoid sun exposure or failing that, use of sunscreen at all times when out in the sun, our participants undoubtedly were getting sunlight exposure as seen by a seasonal variation in 25(OH)D.

In conclusion, we found a 20% rate of vitamin D insufficiency (\<75 nmol/L) in a large, well-nourished cohort of pregnant women. Fifty percent of women who were classified as vitamin D insufficient (\<75 nmol/L) consumed the RDA from both diet and supplements. This finding extends the literature suggesting that 600 IU/day may not be enough to achieve vitamin D status \>75 nmol/L in pregnant women residing in higher latitudes with limited sun exposure. This cohort provided a vehicle for exploring this association, and problems noted in this best-case scenario group of educated and health-conscious women suggest the importance of interventions aimed at all Canadian pregnant women. These findings, together with existing data, highlight the need for re-evaluation of our current vitamin D recommendations for pregnant women residing in countries with higher latitude.
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25(OH)D~2~

:   25-hydroxyergocalciferol

25(OH)D~3~

:   25-hydroxycholecalciferol

3-epi-25(OH)D~3~

:   3-epi-25-hydroxycholecalciferol

LC-MS/MS

:   Liquid chromatography-tandem mass spectrometry
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